ABBV vs MS: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Morgan Stanley — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-29.
AbbVie Inc. · Healthcare
$197.69
+6.3% upside to fair value
Grade C
High Quality
VS
Morgan Stanley · Financial Services
$189.30
+45.0% upside to fair value
Grade C
High Quality
QuantHub Verdict
MS has more upside to fair value
(+45.0%).
MS trades at a lower forward P/E
(16.4x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
MS |
| Current Price |
$197.69 |
$189.30 |
| Fair Value Estimate |
$210.22 |
$274.49 |
| Upside to Fair Value |
+6.3%
|
+45.0%
|
| Market Cap |
$349.7B |
$300.6B |
| Forward P/E |
83.3x
|
16.4x
|
| EV / EBITDA |
23.4x
|
24.4x
|
| Price / Sales |
5.7x
|
2.5x
|
| Price / FCF |
18.7x
|
-16.8x
|
| Revenue Growth YoY |
+10.0%
|
+18.8%
|
| Gross Margin |
70.2%
|
58.0%
|
| Operating Margin |
26.7%
|
19.5%
|
| Return on Equity |
-361.6%
|
16.7%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.35%
|
—
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
Morgan Stanley is a leading global financial services firm operating in Institutional Securities, Wealth Management, and Investment Management. The company benefits from a durable competitive moat supported by its systemically important status, diversified revenue streams, and strong management with a 36-year veteran CEO. Despite solid fundamentals including 14.2% revenue growth in 2025 and 16.7%…
Accumulation Zones
| Metric |
ABBV |
MS |
| Zone Low |
$157.66 |
$205.87 |
| Zone High |
$178.69 |
$233.32 |
| In Buy Zone? |
No
|
Yes
|